SELLAS Life Sciences Group, Inc. Share Price & Technical Analysis
SLS · $7.78 (+2.91%)
Healthcare / Biotechnology
$7.78
+2.91%
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or C…
Price chart
Seasonality
May has 5 positive and 0 negative years (last 5 years shown)
59% return in May, 12% avg return in past 3 year May month.
81% return in 2026, 57% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 32% | -11% | 14% | 59% | – | – | – | – | – | – | – | 81% |
| 25 | 45% | -29% | -8% | 36% | 6% | 22% | -27% | 19% | -20% | 13% | -11% | 138% | 183% |
| 24 | -45% | 67% | 0% | 20% | 8% | -14% | 0% | 8% | -8% | 0% | 0% | -9% | 26% |
| 23 | 32% | -48% | -18% | 0% | 21% | -6% | 7% | -6% | 7% | -37% | 0% | 10% | -39% |
| 22 | -5% | 15% | 8% | -36% | 7% | -27% | 18% | 19% | -35% | 135% | -51% | 0% | 48% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$948.50M
P/E ratio
—
52W high
$9.10
52W low
$1.39
Volume
1,06,94,192
Beta
2.24
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is SELLAS Life Sciences Group, Inc. share price today?
- SELLAS Life Sciences Group, Inc. (SLS) last traded around $7.78 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SLS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SLS. Download the app for real-time alerts.
- How can I analyze SELLAS Life Sciences Group, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.